Merck & Co Inc - SIC # 2834 - PHARMACEUTICAL PREPARATIONS

Ticker Exchange SIC # Website Latest Ticker
MRK New York 2834 https://www.merck.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Merck & Co Inc

Health Canada Approves KEYTRUDA® as a first-line treatment for adult patients with locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma in combination with fluoropyrimidine- and platinum-containing chemotherapy - Apr 19th, 2024 11:04 am
13 Best Low Volatility Stocks to Buy According to Hedge Funds - Apr 18th, 2024 8:27 pm
Merck Insiders Sold US$15m Of Shares Suggesting Hesitancy - Apr 17th, 2024 11:00 am
10 Best Low Volatility ETFs To Buy - Apr 15th, 2024 11:48 am
7 A-Rated Aggressive Biotech Stocks to Bet On in 2024 - Apr 12th, 2024 10:40 am
Merck & Co., Inc.'s (NYSE:MRK) Stock Financial Prospects Look Bleak: Should Shareholders Be Prepared For A Share Price Correction? - Apr 11th, 2024 2:00 pm
Moderna (MRNA) Up 6% on Upbeat Data From Cancer Jab Study - Apr 10th, 2024 2:59 pm
Company News for Apr 10, 2024 - Apr 10th, 2024 1:25 pm
Golden Years Gainers: 3 Stocks to Fund Your Dream Retirement - Apr 8th, 2024 6:00 pm
The 3 Most Undervalued S&P 500 Stocks to Buy in April 2024 - Apr 7th, 2024 6:00 pm
10 Best Weight Loss Drug Stocks to Buy Now - Apr 7th, 2024 12:47 am
The three-year decline in earnings for Merck NYSE:MRK) isn't encouraging, but shareholders are still up 93% over that period - Apr 6th, 2024 1:01 pm
Merck (MRK) Rises Yet Lags Behind Market: Some Facts Worth Knowing - Apr 5th, 2024 9:45 pm
Merck puts KRAS cancer drug competitor to the test - Apr 4th, 2024 11:38 am
Merck Initiates Phase 3 Clinical Trial of MK-1084, an Investigational Oral KRAS G12C Inhibitor, in Combination with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Certain Patients With Metastatic Non-Small Cell Lung Cancer - Apr 4th, 2024 10:45 am
Merck (MRK) Stock Sinks As Market Gains: What You Should Know - Apr 3rd, 2024 9:50 pm
REJOICE-Ovarian01 Phase 2/3 Trial of Raludotatug Deruxtecan Initiated in Patients with Platinum-Resistant Ovarian Cancer - Apr 3rd, 2024 12:00 pm
Why Merck (MRK) is a Top Momentum Stock for the Long-Term - Apr 1st, 2024 1:50 pm
Merck to Hold First-Quarter 2024 Sales and Earnings Conference Call April 25 - Apr 1st, 2024 10:45 am
3 Strong Buy Healthcare Stocks to Add to Your Q2 Must-Watch List - Mar 29th, 2024 2:51 pm